“Expanding our reach through Molecular Devices and with the strength of our combined technologies, we will enable more clients to overcome bottlenecks and maximize their single-cell cloning, CRISPR gene-editing, and single-cell omics assays as well as their cell line development workflows.” “Selecting Molecular Devices as an exclusive provider was an easy decision to make, as we share a purpose to help scientists develop safer, more efficient biotherapies faster, and at lower costs,” said Georges Muller, SEED Biosciences’ CEO and co-founder. Alternatively, the automated DispenCell Single-Cell Dispenser requires just one round of cloning and a single plate, offering significant efficiency improvements. However, isolating a monoclonal cell population by the manual and time-consuming limiting dilution method – which can include three rounds of cloning – leads to high variability in results. Accurate single-cell isolation with immediate, traceable proof of monoclonality is critical to a successful cell line development process.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |